Dr. Monastyrskyi joined the faculty at Moffitt Cancer Center & Research Insitute in April 2019 as an Assistant Member in the Department of Drug Discovery and Molecular Medicine (MM) Program.
He received his Ph.D. in chemistry from the University of South Florida, where he worked with Prof. Roman Manetsch on the synthesis of antimalarial agents based on a 3-aryl-4(1H)-quinolone core structure.
His postdoctoral studies (NIH F32 NRSA Fellow) in synthetic methodology development and drug discovery were carried out at The Scripps Research Institute under the direction of Prof. William R. Roush.
His lab at Moffitt focuses on medicinal chemistry, synthetic organic chemistry, and chemical biology.
Solomon received his Ph.D. from the University of South Australia under the mentorship of Prof. Shudong Wang in 2017. During his graduate studies, he was involved in targeting cyclin-dependent kinases (CDKs) for cancer therapy. His work has resulted in the development, for the first time, of selective, ATP-competitive CDK4 and dual CDK4/6 inhibitors. At Moffitt, Solomon is focusing on targeting transcriptional CDK12 and CDK13 for treatment of cancer.
Alisa received her Ph.D. in Organic Chemistry from the State Scientific Institution "Institute for Single Crystals" of National Academy of Sciences of Ukraine (2019), where she worked with Prof. Valentyn A. Chebanov on studying properties of 3(5)-aminoisoxazoles in reactions with carbonyl compounds. At Moffitt, her research is focused on developing new selective ULK1 kinase inhibitors to affect tumors cells' autophagy.